Usana Health Sciences Inc (USNA) financial statements: income statement, balance sheet and cash flow
Usana Health Sciences Inc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Jan 3, 2026 · FY), Usana Health Sciences Inc reported revenue of $925.3M (+8.3% year on year) and net income of $11.5M (-72.7% year on year).
Income statement
Usana Health Sciences Inc income statement, fiscal years
Line item
Jan 3, 2026 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Net sales
$925.3M
$854.5M
$921.0M
$998.6M
Cost of sales
$200.9M
$161.2M
$176.7M
$193.9M
Gross profit
$724.4M
$693.3M
$744.3M
$804.7M
Brand Partner incentives
$336.2M
—
—
—
Selling, general and administrative
$337.4M
$263.3M
$257.0M
$262.3M
Impairment
$7.0M
—
—
—
Cost realignment
$6.5M
—
—
—
Total operating expenses
$687.0M
$627.0M
$651.2M
$697.1M
Earnings from operations
$37.4M
$66.3M
$93.1M
$107.6M
Interest income
$2.4M
$11.3M
$9.6M
$3.8M
Interest expense
($842.0K)
($281.0K)
($262.0K)
($192.0K)
Other, net
$2.5M
($1.0M)
$7.0K
($2.6M)
Other income (expense), net
$4.1M
$10.0M
$9.4M
$1.0M
Earnings before income taxes
$41.5M
$76.4M
$102.5M
$108.6M
Income taxes
$30.1M
$34.3M
$38.7M
$39.3M
Less: Net earnings attributable to redeemable noncontrolling interest
$717.0K
$30.0K
—
—
Net earnings attributable to USANA
$10.8M
$42.0M
$63.8M
$69.3M
Basic (in dollars per share)
$0.58
$2.20
$3.31
$3.60
Diluted (in dollars per share)
$0.58
$2.19
$3.30
$3.59
Basic (in shares)
18.5M
19.1M
19.3M
19.3M
Diluted (in shares)
18.6M
19.2M
19.3M
19.3M
Net earnings
$11.5M
$42.1M
$63.8M
$69.3M
Foreign currency translation adjustment
$7.2M
($9.4M)
($1.3M)
($15.1M)
Tax benefit (expense) related to foreign currency translation adjustment
($658.0K)
$434.0K
$390.0K
$1.9M
Other comprehensive income (loss), net of tax
$6.5M
($9.0M)
($908.0K)
($13.2M)
Comprehensive income
$18.0M
$33.1M
—
—
Less: comprehensive income attributable to redeemable noncontrolling interest
$717.0K
$30.0K
—
—
Comprehensive income attributable to USANA
$17.3M
$33.1M
$62.9M
$56.1M
Usana Health Sciences Inc income statement, quarters
Line item
Jul 4, 2026 · Q2
Apr 4, 2026 · Q1
Sep 27, 2025 · Q3
Jun 28, 2025 · Q2
Net sales
$223.3M
$250.2M
$213.7M
$235.8M
Cost of sales
$48.3M
$59.4M
$48.8M
$50.2M
Gross profit
$174.9M
$190.8M
$164.9M
$185.7M
Brand Partner incentives
$83.5M
$88.7M
$77.7M
$87.0M
Selling, general and administrative
$82.3M
$88.3M
$85.9M
$81.9M
Goodwill impairment
$29.1M
—
—
—
Total operating expenses
$194.9M
$176.9M
$163.6M
$168.9M
(Loss) earnings from operations
($20.0M)
$13.9M
$1.2M
$16.7M
Interest income
$595.0K
$437.0K
$578.0K
$619.0K
Interest expense
$0
($240.0K)
($49.0K)
($259.0K)
Other, net
$501.0K
$1.4M
$41.0K
$1.7M
Other income (expense), net
$1.1M
$1.6M
$570.0K
$2.1M
(Loss) earnings before income taxes
($18.9M)
$15.5M
$1.8M
$18.8M
Income taxes
$9.1M
$8.5M
$8.5M
$8.4M
Net (loss) earnings attributable to redeemable noncontrolling interest
($6.6M)
($556.0K)
($140.0K)
$789.0K
Net (loss) earnings attributable to USANA
($21.4M)
$7.5M
($6.5M)
$9.7M
Basic (in dollars per share)
-$1.16
$0.41
-$0.36
$0.52
Diluted (in dollars per share)
-$1.16
$0.41
-$0.36
$0.52
Basic (in shares)
18.5M
18.4M
18.3M
18.5M
Diluted (in shares)
18.5M
18.4M
18.3M
18.5M
Net (loss) earnings
($28.0M)
$7.0M
($6.7M)
$10.4M
Foreign currency translation adjustment
$1.4M
$1.9M
$112.0K
$3.7M
Tax (expense) benefit related to foreign currency translation adjustment
($608.0K)
($136.0K)
($52.0K)
($270.0K)
Other comprehensive income (loss), net of tax
$760.0K
$1.7M
$60.0K
$3.4M
Comprehensive income (loss)
($27.2M)
$8.7M
($6.6M)
$13.8M
Comprehensive (loss) income attributable to redeemable noncontrolling interest
($6.6M)
($556.0K)
($140.0K)
$789.0K
Comprehensive (loss) income attributable to USANA
($20.6M)
$9.3M
($6.5M)
$13.1M
Balance sheet
Usana Health Sciences Inc balance sheet, fiscal years
Line item
Jan 3, 2026 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$158.4M
$181.8M
$330.4M
$288.4M
Inventories
$102.6M
$69.7M
$61.5M
$67.1M
Prepaid expenses and other current assets
$27.4M
$27.7M
$25.9M
$28.9M
Total current assets
$288.4M
$279.2M
$417.7M
$384.4M
Property and equipment, net
$94.4M
$94.6M
$99.8M
$97.8M
Goodwill
$138.0M
$144.2M
$17.1M
$17.4M
Intangible assets, net
$133.2M
$151.8M
$29.9M
$32.4M
Deferred tax assets
$27.2M
$19.6M
$13.3M
$9.8M
Other assets
$61.8M
$58.8M
$54.9M
$54.8M
Total assets
$742.9M
$748.2M
$632.8M
$596.5M
Accounts payable
$17.3M
$12.0M
$10.1M
$11.0M
Line of credit
$14.0M
$23.0M
$786.0K
—
Other current liabilities
$97.3M
$104.6M
$108.0M
$132.8M
Total current liabilities
$128.6M
$139.6M
$118.8M
$143.8M
Deferred tax liabilities
$4.9M
$4.1M
$4.6M
$4.1M
Other long-term liabilities
$23.2M
$18.2M
$12.2M
$14.2M
Total liabilities
$156.6M
$161.9M
—
—
Redeemable noncontrolling interest
$53.2M
$54.2M
—
—
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 18,281 as of January 3, 2026 and 19,064 as of December 28, 2024
18.0K
19.0K
19.0K
19.0K
Additional paid-in capital
$83.5M
$75.8M
$65.7M
$55.6M
Retained earnings
$465.7M
$478.9M
$445.2M
$391.6M
Accumulated other comprehensive income (loss)
($16.2M)
($22.7M)
($13.7M)
($12.8M)
Total stockholders' equity attributable to USANA
$533.1M
$532.1M
$497.2M
$434.5M
Total liabilities, redeemable noncontrolling interest, and stockholders' equity
$742.9M
$748.2M
$632.8M
$596.5M
Usana Health Sciences Inc balance sheet, quarters
Line item
Jul 4, 2026
Apr 4, 2026
Sep 27, 2025
Jun 28, 2025
Cash and cash equivalents
$168.6M
$162.8M
$145.3M
$151.3M
Trade accounts receivable (net of allowance of $92 and $137, respectively)
$3.3M
$9.7M
—
—
Inventories
$86.3M
$96.4M
$90.8M
$83.3M
Prepaid expenses and other current assets
$22.8M
$25.5M
$27.9M
$27.3M
Total current assets
$281.1M
$294.2M
$264.1M
$261.9M
Property and equipment, net
$94.3M
$94.6M
$96.2M
$96.5M
Goodwill
$109.1M
$138.1M
$144.3M
$144.2M
Intangible assets, net
$124.6M
$128.9M
$138.2M
$142.7M
Deferred tax assets
$29.5M
$25.2M
$24.2M
$26.4M
Other assets
$64.6M
$57.9M
$59.7M
$62.7M
Total assets
$703.2M
$739.0M
$726.6M
$734.5M
Accounts payable
$15.4M
$16.2M
$16.2M
$17.9M
Line of credit
$0
$14.0M
$0
$0
Other current liabilities
$90.2M
$87.0M
$102.4M
$103.7M
Total current liabilities
$105.7M
$117.2M
$118.7M
$121.6M
Deferred tax liabilities
$4.7M
$5.1M
$4.5M
$4.7M
Other long-term liabilities
$21.9M
$21.9M
$21.9M
$22.7M
Total liabilities
$132.2M
$144.2M
$145.0M
$149.0M
Redeemable noncontrolling interest
$44.7M
$51.2M
$53.5M
$54.5M
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 18,463 as of July 4, 2026 and 18,281 as of January 3, 2026
18.0K
18.0K
18.0K
18.0K
Additional paid-in capital
$88.1M
$84.7M
$79.8M
$76.4M
Retained earnings
$451.9M
$473.2M
$467.5M
$474.0M
Accumulated other comprehensive income (loss)
($13.7M)
($14.4M)
($19.3M)
($19.3M)
Total stockholders' equity attributable to USANA
$526.3M
$543.5M
$528.1M
$531.1M
Total liabilities, redeemable noncontrolling interest, and stockholders' equity
$703.2M
$739.0M
$726.6M
$734.5M
Cash flow statement
Usana Health Sciences Inc cash flow statement, fiscal years
Line item
Jan 3, 2026 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Net earnings
$11.5M
$42.1M
$63.8M
$69.3M
Depreciation and amortization
$32.6M
$14.5M
$12.7M
$13.4M
Right-of-use asset reduction
$7.1M
$7.7M
$7.7M
$8.0M
(Gain) loss on sale of property and equipment
($2.1M)
$1.0K
$10.0K
$141.0K
Equity-based compensation expense
$13.8M
$14.6M
$14.6M
$13.3M
Deferred income taxes
($7.1M)
($6.7M)
($2.7M)
($7.2M)
Inventory write-down
$2.7M
$1.9M
$2.6M
—
Impairment
$7.0M
—
—
—
Inventories
($34.7M)
($2.1M)
$2.4M
$21.9M
Prepaid expenses and other assets
$621.0K
($2.9M)
$110.0K
($3.3M)
Accounts payable
$5.2M
($1.3M)
($428.0K)
($2.7M)
Other liabilities
($14.2M)
($6.7M)
($30.0M)
($9.1M)
Net cash provided by (used in) operating activities
$22.3M
$61.0M
$70.6M
$103.9M
Proceeds from the settlement of net investment hedges
$0
$1.1M
$3.8M
$4.6M
Payments for net investment hedge
($1.1M)
($870.0K)
($1.3M)
$0
Proceeds from acquisition working capital adjustment
$865.0K
—
—
—
Payments to acquire businesses, net of cash acquired
$0
($203.3M)
—
($6.5M)
Proceeds from sale of property and equipment
$3.9M
$64.0K
$15.0K
$7.0K
Purchases of property and equipment
($13.8M)
($10.1M)
($14.5M)
($10.4M)
Net cash provided by (used in) investing activities
($10.1M)
($213.1M)
($12.0M)
($12.4M)
Repurchase of common stock
($27.5M)
($9.4M)
($11.6M)
($25.4M)
Borrowings on line of credit
$17.6M
$23.7M
$1.5M
$11.0M
Payments on line of credit
($26.6M)
($1.5M)
($750.0K)
($11.0M)
Payments related to tax withholding for net-share settled equity awards
($2.3M)
($3.2M)
($3.1M)
($4.7M)
Distributions to redeemable noncontrolling interest
($1.7M)
—
—
—
Payments for contingent consideration
$0
$0
($338.0K)
—
Net cash provided by (used in) financing activities
($40.6M)
$9.6M
($14.2M)
($30.1M)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
$5.1M
($6.2M)
($2.5M)
($13.8M)
Net increase (decrease) in cash, cash equivalents, and restricted cash
($23.3M)
($148.7M)
$41.9M
$47.7M
Cash, cash equivalents, and restricted cash at beginning of period
$184.5M
$333.2M
$291.3M
$243.7M
Cash, cash equivalents, and restricted cash at end of period
$161.2M
$184.5M
$333.2M
$291.3M
Cash and cash equivalents
$158.4M
$181.8M
$330.4M
$288.4M
Restricted cash included in other assets
$2.9M
$2.7M
$2.8M
—
Total cash, cash equivalents, and restricted cash
$161.2M
$184.5M
$333.2M
$291.3M
Interest
$663.0K
$76.0K
$68.0K
$49.0K
Right-of-use assets obtained in exchange for lease obligations
$8.6M
$12.5M
$5.7M
$5.6M
Net working capital adjustment receivable
$0
$778.0K
—
—
Accrued purchases of property and equipment
$1.0K
$42.0K
$117.0K
$679.0K
Accrued excise tax for repurchase of common stock
$231.0K
$39.0K
$54.0K
—
Usana Health Sciences Inc cash flow statement, quarters
Line item
Jul 4, 2026 · YTD
Apr 4, 2026 · Q1
Sep 27, 2025 · YTD
Jun 28, 2025 · YTD
Net (loss) earnings
($21.0M)
$7.0M
$13.1M
$19.7M
Depreciation and amortization
$16.0M
$8.3M
$24.0M
$16.1M
Right-of-use asset reduction
$3.0M
$1.5M
$5.4M
$3.8M
Loss on sale of property and equipment
$26.0K
$13.0K
$124.0K
$29.0K
Equity-based compensation expense
$6.9M
$3.5M
$10.1M
$6.5M
Deferred income taxes
($3.2M)
$2.1M
($4.5M)
($6.5M)
Inventory write-down
$3.1M
$1.3M
$2.4M
$2.0M
Goodwill impairment
$29.1M
—
—
—
Trade accounts receivable
$959.0K
($5.4M)
—
—
Inventories
$9.4M
$6.6M
($21.1M)
($13.0M)
Prepaid expenses and other assets
$715.0K
($1.7M)
($199.0K)
($460.0K)
Accounts payable
($1.9M)
($1.5M)
$4.1M
$5.8M
Other liabilities
($10.0M)
($11.9M)
($7.7M)
($6.3M)
Net cash provided by (used in) operating activities
$33.1M
$9.8M
$25.7M
$27.7M
Payments for the settlement of net investment hedges
($917.0K)
—
—
—
Payments for net investment hedge
$0
$0
($1.1M)
($1.1M)
Proceeds from acquisition working capital adjustment
$0
—
$865.0K
$865.0K
Proceeds from sale of property and equipment
$63.0K
$48.0K
$0
$0
Purchases of property and equipment
($5.8M)
($2.6M)
($11.0M)
($7.8M)
Net cash provided by (used in) investing activities
($6.7M)
($2.6M)
($11.2M)
($8.0M)
Repurchase of common stock
$0
$0
($27.5M)
($27.5M)
Borrowings on line of credit
$9.0M
$4.0M
$1.6M
$1.6M
Payments on line of credit
($23.0M)
($4.0M)
($24.6M)
($24.6M)
Payments related to tax withholding for net-share settled equity awards
($2.3M)
($2.3M)
($2.3M)
($2.2M)
Distributions to redeemable noncontrolling interest
($1.4M)
($1.4M)
($1.3M)
($379.0K)
Net cash provided by (used in) financing activities
($17.7M)
($3.6M)
($54.1M)
($53.1M)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
$1.5M
$896.0K
$3.2M
$3.0M
Net increase (decrease) in cash, cash equivalents, and restricted cash
$10.3M
$4.4M
($36.4M)
($30.4M)
Cash, cash equivalents, and restricted cash at beginning of period
$161.2M
$161.2M
$184.5M
$184.5M
Cash, cash equivalents, and restricted cash at end of period
$171.5M
$165.7M
$148.2M
$154.1M
Cash and cash equivalents
$168.6M
$162.8M
$145.3M
$151.3M
Restricted cash included in other assets
$2.9M
$2.9M
$2.8M
$2.8M
Total cash, cash equivalents, and restricted cash
$171.5M
$165.7M
$148.2M
$154.1M
Interest
$473.0K
$242.0K
$662.0K
$662.0K
Income taxes
$22.9M
$9.1M
$31.5M
$25.3M
Income tax refund
$249.0K
$0
$149.0K
$45.0K
Right-of-use assets obtained in exchange for lease obligations